Darmstadt, Germany, November 19, 2015 – Merck, a leading science and technology company, today announced that a research agreement has been signed with the University of Cape Town (UCT) South Africa to co-develop a new R&D platform aimed at identifying new lead programs for potential treatments against malaria, with the potential to expand it to other tropical diseases.
Kelly didn’t have the easiest start to his academic career. After attending three different primary schools, he had to retake his final examinations in order to attend secondary school in Kasama, the capital of the Northern Province of Zambia. At the end of school, he was unsuccessful in his application to study accounting at university and was forced to take a step back and reconsider his options. In this time, Kelly remembered his fascination with chemical reactions and colour changes at school and decided to study chemistry instead.
Le paludisme est un fléau qui déchire l’Afrique depuis des décennies. Les compagnies pharmaceutiques annoncent régulièrement des avancées dans la recherche d’un vaccin. En Afrique du Sud, des scientifiques pensent avoir trouvé un raccourci vers un traitement efficace.